Weight Loss Medications for Patients with CHF and COPD
For patients with chronic heart failure and COPD who have obesity, GLP-1 receptor agonists—specifically semaglutide 2.4 mg weekly or tirzepatide—are the preferred weight loss medications, particularly if the patient has HFpEF (heart failure with preserved ejection fraction). 1
Key Algorithmic Approach
Step 1: Determine Heart Failure Type
If HFpEF (EF ≥45%):
Semaglutide 2.4 mg weekly is strongly recommended based on the STEP-HFpEF trials showing significant improvements in:
Tirzepatide showed even greater benefits in the SUMMIT trial with 11.6% weight loss and similar improvements in functional status 1
If HFrEF (reduced ejection fraction):
- Exercise extreme caution with GLP-1 agonists—specifically liraglutide has been associated with increased risk of HF hospitalizations and arrhythmias in advanced HFrEF 1
- Semaglutide and tirzepatide have not been adequately studied in HFrEF populations
- Focus on lifestyle interventions and exercise programs instead
Step 2: Avoid Older Weight Loss Medications
Do NOT use these agents in patients with CHF:
- Phentermine/topiramate, naltrexone/bupropion, and orlistat have "minimal efficacy and limited adverse effects, particularly in individuals with HF" 1
- Historical agents (fenfluramine, sibutramine, lorcaserin) were withdrawn due to cardiovascular safety concerns 1
Step 3: COPD Considerations
The presence of COPD does not contraindicate GLP-1 receptor agonists. Key points:
- β-blockers are safe and beneficial in patients with both COPD and HFrEF—use β1-selective agents (metoprolol, bisoprolol) which improve survival and reduce both HF and COPD exacerbations 3
- COPD-induced hyperinflation and HF-related congestion create bidirectional hemodynamic stress, making weight reduction particularly important 3
- No specific contraindications exist for semaglutide or tirzepatide in COPD patients
Step 4: Monitoring Strategy
When initiating GLP-1 receptor agonists:
- Watch for gastrointestinal side effects (nausea, vomiting) which were the most common adverse events in trials
- Monitor for worsening HF symptoms, though serious adverse events were actually lower with semaglutide (17.7%) versus placebo (28.8%) in HFpEF trials 2
- Track inflammatory markers (CRP decreased 36% with semaglutide) and NT-proBNP levels 1
- Assess functional capacity with 6-minute walk tests
Critical Caveats
The obesity paradox in heart failure suggests better prognosis with higher BMI in observational studies 4, but this does not apply to intentional weight loss with modern pharmacotherapy. The STEP-HFpEF and SUMMIT trials definitively show that intentional weight loss with GLP-1 agonists improves mortality and morbidity outcomes in HFpEF 1.
Bariatric surgery has shown mixed results with some HFrEF patients developing perioperative worsening of HF, making it a less favorable option compared to pharmacotherapy 4.
Lifestyle interventions alone (diet and exercise) are appropriate to attempt but often unsustainable for meaningful long-term weight loss 1. However, exercise specifically improves functional status in HFpEF and should be combined with pharmacotherapy 1.
Bottom Line Algorithm
- HFpEF + obesity + COPD → Semaglutide 2.4 mg weekly (first-line) or tirzepatide
- HFrEF + obesity + COPD → Lifestyle modification and exercise programs; avoid GLP-1 agonists
- All patients → Continue β1-selective β-blockers if indicated for HF; avoid older weight loss medications